Is Align Technology (ALGN) Fully Priced As EU Antitrust Scrutiny Clouds Its Valuation?

July 5, 2026 - 19:11

The European Commission has launched a formal antitrust investigation into Align Technology, targeting the company's iTero scanners and the Invisalign ecosystem. The probe has put a sharper focus on the stock's risk profile, with investors now weighing how potential regulatory outcomes could shift sentiment.

Despite the cloud of scrutiny, Align Technology's share price has held up reasonably well. Over the past month, the stock returned 10.0%, and it has gained 18.3% year to date. That resilience raises the question of whether the current valuation already reflects the antitrust risks or if the market is underestimating the potential fallout.

The investigation centers on whether Align uses its dominant position in digital orthodontics to stifle competition. If the EU finds evidence of anti-competitive practices, the company could face fines or be forced to change its business model in Europe. That would likely pressure margins and slow growth in a key region.

For now, the stock's recent performance suggests many investors are betting the probe will not lead to severe penalties. But with the EU known for taking a hard line on tech and medical device companies, the outcome remains uncertain. Analysts are watching closely for any signs of escalation, as a negative ruling could quickly erase the year's gains.